No tax




Security policy (edit with Customer reassurance module)


Delivery policy (edit with Customer reassurance module)


Return policy (edit with Customer reassurance module)

Tradename: Levocetirizine

Dosage Form:

film coated tablets

1 pill contains:
active ingredient: levocetirizine dihydrochloride 5.00 mg;
excipients: microcrystalline cellulose 30.00 mg, lactose monohydrate 63.50 mg, colloidal silicon dioxide 0.50 mg, Magnesium stearate 1.00 mg;
Opadray shell Y1-7000H white: macrogol-400 0.1875 mg, titanium dioxide (E171) 0.9375 mg, hypromellose-2910 (E464) 1.875 mg.

Pharmacotherapeutic group:

H1-histamine receptor antagonist

Pharmacological properties
Levocetirizine - Cetirizine enantiomer, belongs to the group of competitive histamine antagonists, blocks the H1-histamine receptors (H1-GR), has a high level of selectivity for H1-GR. Levocetirizine has an effect on the histamine-dependent stage of allergic reactions, inhibiting eotaxins that promote transendothelial migration of eosinophils, blocking the expression of vascular cell adhesion molecule 1, reduces eosinophil migration, reduces vascular permeability, limits the release of inflammatory mediators. It prevents the development and facilitates the course of an allergic reaction, has anti-exudative, antipruritic action, practically does not have anticholinergic and antiserotonin action.In therapeutic doses, it has almost no sedative effect, does not change the electrocardiogram (ECG) indices, in particular, the QT interval.

The pharmacokinetic parameters of levocetirizine vary linearly and are practically the same as cetirizine pharmacokinetics.
Suction. After oral administration, levocetirizine is rapidly absorbed in the gastrointestinal tract. Meal does not affect the degree of absorption, although its rate decreases. After a single ingestion in a therapeutic dose, the maximum concentration (Cmax) in the blood plasma in adults is reached after 0.9 h and is 207 ng / ml, after repeated administration at a dose of 5 mg / day - 308 ng / ml. Bioavailability is 100%.
Distribution. Equilibrium concentration is reached after 2 days. The binding of levocetirizine to plasma proteins is 90%. The volume of distribution of the drug is 0.4 l / kg.
Metabolism. Less than 14% is metabolized in the liver by including the processes of oxidation of aromatic compounds, N- and O-dealkylation and conjugation of Taurine. Dealkylation occurs in the presence of a CYP3A4 isoenzyme, and numerous and / or unidentified P450 isoenzymes are involved in the oxidation of aromatic compounds. Levocetirizine does not affect the activity of CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4 isoenzymes at a concentration significantly higher than C max after a 5 mg oral dose. Due to the low level of metabolism and the lack of metabolic potential, the interaction of levocetirizine with other drugs seems unlikely.
Inference.In adults, the elimination half-life (T1 / 2) is 7.9 ± 1.9 h, the total clearance is 0.63 ml / min / kg. Fully excreted from the body within 96 hours. About 85.4% of the dose is excreted by the kidneys unchanged by glomerular filtration and tubular secretion; about 12.9% is excreted in the feces.
Pharmacokinetics in special clinical situations. In patients with renal insufficiency (creatinine clearance (CC) less than 40 ml / min), the clearance of levocetirizine decreases, and T1 / 2 increases (in patients on hemodialysis, the total clearance decreases by 80%), which requires a corresponding change in dosing regimen. Less than 10% of levocetirizine is removed during the standard 4-hour hemodialysis procedure. In children of the younger age group T1 / 2 decreases.

Indications for use 
Symptomatic treatment:

  • year-round allergic rhinitis;
  • seasonal allergic rhinitis;
  • chronic idiopathic urticaria.

Hypersensitivity to levocetirizine and other components of the drug; hypersensitivity to piperazine derivatives; end-stage renal disease (CC less than 10 ml / min); lactose intolerance, lactase deficiency, glucose-galactose malabsorption; children up to 6 years; pregnancy; breastfeeding period.

Medium and severe renal failure (CC more than 10 ml / min, but less than 50 ml / min); advanced age (reduction of glomerular filtration is possible).

Use during pregnancy and during breastfeeding 
There is not enough clinical data on the use of levocetirizine in pregnant women, so do not use the drug Levocetirizine -Teva during pregnancy.
Levocetirizine is excreted in breast milk. If necessary, use of the drug Levocetirizine -Tech breastfeeding should be discontinued.

Dosage and administration 
Inside, regardless of the meal. The pills are chewed and washed down with water.
Adults and children over 6 years: 5 mg once a day, daily.
The duration of application depends on the duration of symptoms of the disease. On average, use 3-6 weeks, in the case of a short period of exposure to the allergen may be enough use within 1 week. With a long chronic course of the disease, treatment can last up to 6 months.
Elderly patients: no need to adjust the dose.
Patients with impaired renal function: the dose should be adjusted depending on the CC (see table).

Renal failure QC (ml / min) Dose and frequency of administration Norm more than 80 5 mg / day Mild 50-79 5 mg / day Average degree 30-49 5 mg / day 1 every 2 days Severe degree less than 30 5 mg / day 1 time in 3 days Terminal stage (patients on hemodialysis) less than 10 Reception is contraindicated

QC is calculated by the formulas:
for men: body weight (kg) x (140-year-old (full years)) / 72 x plasma plasma creatinine concentration (mg / dL);
for women: 0.85 x QC of men.
Patients with impaired liver function: correction of the dosing regimen is not required.

Side effect 
The frequency of side effects is classified according to the recommendations of the World Health Organization: very often - at least 10%; often not less than 1%, but less than 10%; infrequently - not less than 0.1%, but less than 1%; rarely - not less than 0.01%, but less than 0.1%; very rarely - less than 0.01%, including isolated cases.
From the nervous system: often - headache, drowsiness, aggression, agitation, convulsions; rarely - migraine, dizziness.
On the part of the organ of vision: often - visual impairment.
Since the cardiovascular system: very rarely - tachycardia.
On the part of the respiratory system: very rarely - dyspnea.
On the part of the digestive system: often - dryness of the oral mucosa; infrequently - abdominal pain; very rarely - nausea, dyspepsia, diarrhea, changes in liver function tests, hepatitis.
On the part of the musculoskeletal system: rarely - myalgia.
On the part of the metabolism: rarely - an increase in body weight.
Allergic reactions: very rarely - pruritus, skin rash, urticaria, angioedema, anaphylaxis.
Others: often - fatigue, feeling tired; infrequently - asthenia.

Symptoms: drowsiness (in adults), agitation and anxiety, alternating with sleepiness (in children).
Symptomatic treatment: immediately after taking the drug hold a gastric lavage or induce artificial vomiting.The use of activated charcoal, symptomatic and supportive therapy is recommended. There is no specific antidote. Hemodialysis is ineffective.

Interaction with other drugs 
When studying drug interactions of levocetirizine with pseudoephedrine, cimetidine, Ketoconazole, Erythromycin, Azithromycin, glipizide and diazepam, no clinically significant undesirable interaction was revealed. Simultaneous use with macrolides or ketoconazole did not cause significant changes in the ECG.
With simultaneous use with theophylline (400 mg / day), the total clearance of cetirizine is reduced by 16%, the pharmacokinetic parameters of theophylline do not change.
In some cases, the simultaneous use of levocetirizine with ethanol or drugs that have a depressant effect on the central nervous system (CNS) may increase their influence on the central nervous system, although it has been proven that levocetirizine does not enhance the effect of ethanol.

special instructions 
Do not exceed the recommended daily dose.
The patient must be warned that drinking alcohol during treatment with levocetirizine is not recommended.

Influence on ability to drive motor transport and control mechanisms 
The ability to drive motor vehicles and work with mechanisms when applying levocetirizine at the recommended dose does not change. However, given that during the treatment period, adverse reactions may develop (drowsiness,dizziness) care must be taken during the occupation of potentially hazardous activities that require increased concentration and psychomotor speed.

Storage conditions 
Store at a temperature not higher than 25 ° С.
Keep out of the reach of children.

19 Items